81 articles - From Friday May 09 2025 to Friday May 16 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Clin Gastroenterol Hepatol |
|---|
Effectiveness of six international guidelines using FIB-4 and FibroScan for risk stratification of MASLD in type 2 diabetes. The percentage of T2D patients in diabetes clinics requiring referral to hepatology (12%) was similar across the six pathways, but higher (19%) when VCTE was used as the first line, with a low false negative rate (3%) for advanced fibrosis. |
| J Hepatol |
EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease. These clinical practice guidelines provide comprehensive recommendations for the assessment and perioperative management of patients with cirrhosis undergoing extrahepatic surgery. An individualised patient-centred risk assessment by a multidisciplinary team including hepatologists, surgeons, anaesthesiologists, and other support teams is essential. |
EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. The aim of these EASL guidelines is to provide updated guidance on the diagnosis and management of AIH both in adults and children. Updated guidance on the management of patients with variants and specific forms of AIH is also provided, as is detailed guidance on the management of AIH-associated cirrhosis, including surveillance for portal hypertension and hepatocellular carcinoma, as well as liver transplantation in decompensated cirrhosis. |
EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma. Owing to recent developments and the significant differences in CCA subtypes, EASL commissioned a panel of experts to draft evidence-based recommendations on the management of extrahepatic CCA, comprising distal and perihilar CCA. Particular attention is given to the need for accurate classification systems, the integration of emerging molecular insights, and practical strategies for diagnosis and treatment that reflect real-world clinical scenarios. |
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. The guidelines also discuss emerging biomarkers and evolving definitions of functional and partial cure. Developed through literature review, expert consensus, and a Delphi process, the guidelines aim to equip healthcare providers across disciplines with practical tools to optimise HBV care and outcomes worldwide. |
meta-analyses and systematic reviews
| Clin Gastroenterol Hepatol |
|---|
Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review with Meta-analysis. IFX may be more efficacious than CsA for the treatment of ASUC. Janus kinase inhibitors are promising treatment options in select individuals. Future studies should explore the efficacy of other advanced therapies. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Diabetes Mellitus in Patients With Autoimmune Hepatitis: Frequency, Risk Factors and Effect on Outcome. New-onset DM occurred in 13% of patients with AIH, was related to older age, non-Caucasian ethnicity, higher prednisolone dose, higher BMI at diagnosis and weight gain; and was an independent predictor of all-cause death/transplantation and of cirrhosis development, underlining the need to minimise steroid burden in AIH. |
| Clin Gastroenterol Hepatol |
Association between nonalcoholic fatty liver disease and risk of early onset colorectal cancer. NAFLD is positively associated with an increased risk of early-onset CRC, particularly in the left colon and rectum. These findings highlight the need for multifaceted preventive strategies, including lifestyle interventions and expanded screening for younger populations with NAFLD. |
CT-colonography in Fecal Immunochemical Test Positives in a Colorectal Cancer Screening Program. CTC in FIT-positive screenees was associated with a lower AN detection rate and a higher PCT-CRC rate compared to what is known from colonoscopy. A substantial proportion of complications occurred, and quality reporting was often lacking. This underlines the need for a structured quality assurance program for CTCs performed in FIT-positives. Critical appraisal who to refer for CTC and communication about the benefits and pitfalls of CTC is warranted. |
| Endoscopy |
A novel technique for submucosal tumors in esophagus: mucosal zipper endoscopic resection. MZER seems to provide an optional treatment for proximal or larger esophageal SMTs. The efficacy and safety profiles need further validation through multicenter studies with larger cohorts, given the current limitations of sample size and single-center design. |
| Gastrointest Endosc |
Combined phosphorus-32 implantation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer: a propensity-score weighted landmark analysis. In this comparative study between combined chemotherapy and 32 P microparticles implantation with standard chemotherapy for patients with LAPC, the combination showed better survival, disease control and downstaging. The outcomes highlight the need for a randomized controlled trial. |
Outcomes of Endoscopic Ultrasound-Guided Liver Biopsy Using 22-Gauge vs. 19-Gauge Needles with a Novel Hydrostatic Sampling Technique. When using the HST, EUS-LB with 22G needles meets adequacy standards at high rates similar to 19G needles. The HST may allow for the use of 22G needles in patients at high risk for adverse events or with challenging anatomies. |
| Gut |
| Hepatology |
GPD1L supports glycerol-3-phosphate and triacylglycerol synthesis and promotes tumor progression in hepatocellular carcinoma. GPD1L is overexpressed in human HCCs and associated with worse clinical outcomes. Aberrant GPD1L expression, driven by ELF1, facilitates conversion of DHAP to G3P conversion to support triacylglycerol synthesis in HCC, promoting tumor growth and metastasis. |
Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications. We explore the spatiotemporal diversity of HSCs, highlighting their subpopulations and their specialized roles, as well as the complex bidirectional communications between HSCs, hepatocytes, endothelial cells, macrophages/monocytes, T cells, and tumor cells. By integrating insights from single-cell sequencing, spatial transcriptomics, preclinical data and clinical data, this review aims to provide an updated understanding of how HSC heterogeneity contributes to liver homeostasis and disease and can be targeted for therapeutic purposes. |
| J Hepatol |
Decoding the Resistin-CAP1 Pathway in Intermediate Monocytes Mediating Liver Allograft Rejection. These findings offer insights into the dynamic changes in the alloimmune microenvironment, pinpointing intermediate monocytes as potential diagnostic and immunotherapeutic targets during allograft rejection. This study holds significant importance in advancing non-invasive diagnostic technologies and immunotherapeutic strategies for allogeneic rejection. Impact and implications This study pioneers the application of spatial transcriptomics in liver transplantation, providing a comprehensive analysis of immune cell spatial distribution, complemented by Souporcell-based chimerism assessment. We demonstrate that intermediate monocytes play a pivotal role in T cell-mediated acute rejection via the Resistin-CAP1 signaling axis. Targeting this pathway using nanogold-siRNA technology effectively mitigates rejection and enhances graft survival. These findings contribute novel insights into the mechanisms of transplant rejection and present promising avenues for the development of targeted therapeutic and diagnostic strategies in liver transplantation. |
High inherited risk predicts age-associated increases in fibrosis in patients with MASLD. GRS, PRS-HFC, PRS-5, and PNPLA3 genotypes alone are associated with greater fibrosis per decade, resulting in divergent disease trajectories starting in midlife. Assessing genetic risk in MASLD will identify high-risk patients who require more frequent monitoring. Impact and implications This study provides granular evidence that genetic predisposition, particularly the PNPLA3 G/G genotype, significantly influences the trajectory of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), with a more pronounced impact emerging after the fourth decade of life. These findings highlight the importance of incorporating genetic risk assessment into MASLD management, as it allows for the early identification of high-risk individuals who may benefit from more frequent monitoring and targeted interventions. Given the rising global burden of MASLD, clinicians, researchers, and policymakers should consider integrating genetic stratification into existing risk assessment frameworks to refine screening and surveillance strategies. By optimizing patient selection for non-invasive fibrosis assessment and potential therapeutic interventions, this approach could enhance precision medicine efforts and may improve long-term outcomes. |
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial. Elafibranor was well tolerated in people with PSC and associated with greater biochemical improvements over 12 weeks compared with placebo. A greater magnitude of response was observed with elafibranor 120 mg compared with 80 mg. Impact and implications For people with primary sclerosing cholangitis (PSC), there is a need for a well-tolerated and effective treatment that will enhance quality of life, prevent disease progression, and improve long-term outcomes. Here, we present results from the double-blind period of the phase II ELMWOOD trial in PSC, wherein elafibranor, a peroxisome proliferator-activated receptor-α/δ agonist, demonstrated a favorable safety profile, provided greater biochemical improvements over 12 weeks compared with placebo, and appeared to stabilize markers of fibrosis and improve pruritus. These findings support larger and longer term investigations of elafibranor to explore its therapeutic potential as a treatment for people with PSC. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Clin Gastroenterol Hepatol |
|---|
| Gastroenterology |
| Gastrointest Endosc |
| J Hepatol |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Clin Gastroenterol Hepatol |
|---|
| Endoscopy |
| Gastrointest Endosc |
| Hepatology |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Clin Gastroenterol Hepatol |
| Gastrointest Endosc |
| Gut |
| J Hepatol |